EFTR (eFFECTOR Therapeutics) Ending Cash Position: $15.51 Mil (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is eFFECTOR Therapeutics Ending Cash Position?

eFFECTOR Therapeutics EFTR -62.50% Ending Cash Position is $15.51 Mil as of Mar. 2024.

eFFECTOR Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $15.51 Mil.

eFFECTOR Therapeutics's quarterly Ending Cash Position increased from Sep. 2023 ($5.39 Mil) to Dec. 2023 ($14.88 Mil) and increased from Dec. 2023 ($14.88 Mil) to Mar. 2024 ($15.51 Mil).

eFFECTOR Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($49.70 Mil) to Dec. 2022 ($8.71 Mil) but then increased from Dec. 2022 ($8.71 Mil) to Dec. 2023 ($14.88 Mil).

eFFECTOR Therapeutics Ending Cash Position Related Terms

eFFECTOR Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for eFFECTOR Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

eFFECTOR Therapeutics Ending Cash Position Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Ending Cash Position
15.22 49.70 8.71 14.88

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.31 14.71 5.39 14.88 15.51

eFFECTOR Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

eFFECTOR Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=8.708+6.167
=14.88

eFFECTOR Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=14.875+0.633
=15.51

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $15.51 Mil mean?
eFFECTOR Therapeutics (EFTR) has a Ending Cash Position of $15.51 Mil as of Mar. 2024. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on eFFECTOR Therapeutics and its competitors.
Is eFFECTOR Therapeutics' Ending Cash Position too high?
eFFECTOR Therapeutics' current Ending Cash Position is $15.51 Mil.
How does eFFECTOR Therapeutics' Ending Cash Position compare to NTBLQ and MTEM?
eFFECTOR Therapeutics' Ending Cash Position of $15.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on eFFECTOR Therapeutics and its competitors. eFFECTOR Therapeutics's current Ending Cash Position is $15.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is eFFECTOR Therapeutics stock overvalued right now?
eFFECTOR Therapeutics (EFTR) has a current Ending Cash Position of $15.51 Mil. The current Ending Cash Position is $15.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For eFFECTOR Therapeutics (EFTR), the current Ending Cash Position is $15.51 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

eFFECTOR Therapeutics Business Description

Address 142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).